 |
|
Projected Cost-effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children
Tracy A. Lieu, MD, MPH;
G. Thomas Ray, MBA;
Steven B. Black, MD;
Jay C. Butler, MD;
Jerome O. Klein, MD;
Robert F. Breiman, MD;
Mark A. Miller, MD;
Henry R. Shinefield, MD
JAMA. 2000;283:1460-1468.
Context Pneumococcal conjugate vaccine for infants has recently been found effective against meningitis, bacteremia, pneumonia, and otitis media.
Objective To evaluate the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children.
Design Cost-effectiveness analysis based on data from the Northern California Kaiser Permanente randomized trial and other published and unpublished sources.
Setting and Patients A hypothetical US birth cohort of 3.8 million infants.
Interventions Hypothetical comparisons of routine vaccination of healthy infants, requiring 4 doses of pneumococcal conjugate vaccine (at 2, 4, 6, and 12-15 months), and catch-up vaccination of children aged 2 to 4.9 years requiring 1 dose, with children receiving no intervention.
Main Outcome Measures Cost per life-year saved and cost per episode of meningitis, bacteremia, pneumonia, and otitis media prevented.
Results Vaccination of healthy infants would prevent more than 12,000 cases of meningitis and bacteremia, 53,000 cases of pneumonia, 1 million episodes of otitis media, and 116 deaths due to pneumococcal infection. Before accounting for vaccine costs, the vaccination program would save $342 million in medical and $415 million in work-loss and other costs from averted pneumococcal disease. Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose. At the manufacturer's list price of $58 per dose, infant vaccination would cost society $80,000 per life-year saved or $160 per otitis media episode prevented (other estimated costs would be $3200 per pneumonia case prevented, $15,000 for bacteremia, and $280,000 for meningitis). The cost-effectiveness of an additional program to administer 1 dose of vaccine to children aged 2 to 4.9 years would vary depending on the children's ages, relative risks of pneumococcal disease, and vaccine cost.
Conclusions Pneumococcal conjugate vaccination of healthy US infants has the potential to be cost-effective. To achieve cost savings, its cost would need to be lower than the manufacturer's list price. In addition to tangible costs, the vaccine should be appraised based on the less tangible value of preventing mortality and morbidity from pneumococcal disease.
Author Affiliations: Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Mass (Dr Lieu); Division of Research (Dr Lieu and Mr Ray), Vaccine Study Center (Drs Black and Shinefield), Kaiser Permanente, Oakland, Calif; Department of Pediatrics, Boston City Hospital, Boston University Medical Center, Boston, Mass (Dr Klein); Artic Investigations Program, National Center for Infectious Diseases, Anchorage, Alaska (Dr Butler) and National Vaccine Program Office (Dr Breiman), Centers for Disease Control and Prevention, Atlanta, Ga; and Children's Vaccine Initiative, Geneva, Switzerland (Dr Miller).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Cost-effectiveness of Pneumococcal Vaccine
Chinh Le, Allen S. Meyerhoff, R. Jake Jacobs, Tracy Lieu, G. Thomas Ray, Steven Black, Henry Shinefield, Jay Butler, and Mark Miller
JAMA. 2000;284(4):440-441.
EXTRACT
| FULL TEXT
RELATED ARTICLE
March 15, 2000
JAMA. 2000;283(11):1497-1498.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness
O'Brien et al.
Pediatrics 2009;123:1452-1463.
ABSTRACT
| FULL TEXT
Projected Cost-effectiveness of New Vaccines for Adolescents in the United States
Ortega-Sanchez et al.
Pediatrics 2008;121:S63-S78.
ABSTRACT
| FULL TEXT
Health Care Utilization for Pneumonia in Young Children After Routine Pneumococcal Conjugate Vaccine Use in the United States
Zhou et al.
Arch Pediatr Adolesc Med 2007;161:1162-1168.
ABSTRACT
| FULL TEXT
A Human Monoclonal Immunoglobulin M Reduces Bacteremia and Inflammation in a Mouse Model of Systemic Pneumococcal Infection
Fabrizio et al.
CVI 2007;14:382-390.
ABSTRACT
| FULL TEXT
Cost-effectiveness and Potential Impact of Rotavirus Vaccination in the United States
Widdowson et al.
Pediatrics 2007;119:684-697.
ABSTRACT
| FULL TEXT
Reduction of Frequent Otitis Media and Pressure-Equalizing Tube Insertions in Children After Introduction of Pneumococcal Conjugate Vaccine
Poehling et al.
Pediatrics 2007;119:707-715.
ABSTRACT
| FULL TEXT
Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease.
ElHassan et al.
Arch Pediatr Adolesc Med 2006;160:1070-1076.
ABSTRACT
| FULL TEXT
National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States
Grijalva et al.
Pediatrics 2006;118:865-873.
ABSTRACT
| FULL TEXT
Control of pneumococcal disease in the United Kingdom - the start of a new era.
Clarke
J Med Microbiol 2006;55:975-980.
ABSTRACT
| FULL TEXT
Economic Analysis of Prevaccination Serotesting Compared With Presumptive Immunization for Polio, Diphtheria, and Tetanus in Internationally Adopted and Immigrant Infants
Cohen and Veenstra
Pediatrics 2006;117:1650-1655.
ABSTRACT
| FULL TEXT
Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001
Zhou et al.
Arch Pediatr Adolesc Med 2005;159:1136-1144.
ABSTRACT
| FULL TEXT
Management of Influenza Symptoms in Healthy Children: Cost-effectiveness of Rapid Testing and Antiviral Therapy
Rothberg et al.
Arch Pediatr Adolesc Med 2005;159:1055-1062.
ABSTRACT
| FULL TEXT
Varicella Vaccine, Cost-effectiveness Analyses, and Vaccination Policy
Davis
JAMA 2005;294:845-846.
FULL TEXT
Pertussis in Adolescents and Adults: Should We Vaccinate?
Lee et al.
Pediatrics 2005;115:1675-1684.
ABSTRACT
| FULL TEXT
Overcoming Economic Barriers To The Optimal Use Of Vaccines
Lieu et al.
Health Aff (Millwood) 2005;24:666-679.
ABSTRACT
| FULL TEXT
Community-Acquired Pneumonia in Children: Quantifying the Burden on Patients and Their Families Including Decrease in Quality of Life
Shoham et al.
Pediatrics 2005;115:1213-1219.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States
Shepard et al.
Pediatrics 2005;115:1220-1232.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Defending against Bioterrorism: A Comparison of Vaccination and Antibiotic Prophylaxis against Anthrax
Fowler et al.
ANN INTERN MED 2005;142:601-610.
ABSTRACT
| FULL TEXT
Impact of PCV7 on Invasive Pneumococcal Disease Among Children Younger Than 5 Years: A Population-Based Study
Ramani et al.
Am. J. Public Health 2004;94:958-959.
ABSTRACT
| FULL TEXT
Incidence of Outpatient Visits and Hospitalizations Related to Influenza in Infants and Young Children
O'Brien et al.
Pediatrics 2004;113:585-593.
ABSTRACT
| FULL TEXT
Preferences and Willingness to Pay for Health States Prevented by Pneumococcal Conjugate Vaccine
Prosser et al.
Pediatrics 2004;113:283-290.
ABSTRACT
| FULL TEXT
Postpartum Length of Stay and Newborn Health: A Cost-Effectiveness Analysis
Malkin et al.
Pediatrics 2003;111:e316-322.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Group C Meningococcal Conjugate Vaccine in England and Wales
Rathore
AAP Grand Rounds 2002;8:2-3.
FULL TEXT
Protein conjugate pneumococcal vaccines
Spoulou et al.
BMJ 2002;324:750-751.
FULL TEXT
The Prevention of Pneumococcal Disease in Children
Giebink
NEJM 2001;345:1177-1183.
FULL TEXT
Management of Febrile Children in the Age of the Conjugate Pneumococcal Vaccine: A Cost-Effectiveness Analysis
Lee et al.
Pediatrics 2001;108:835-844.
ABSTRACT
| FULL TEXT
Cost-Effectiveness Analysis of an Intranasal Influenza Vaccine for the Prevention of Influenza in Healthy Children
Luce et al.
Pediatrics 2001;108
:e24-e24.
ABSTRACT
| FULL TEXT
Pneumococcal vaccination: current and future issues
Ortqvist
Eur Respir J 2001;18:184-195.
ABSTRACT
| FULL TEXT
A Pneumococcal Conjugate Vaccine and Acute Otitis Media
Lavin et al.
NEJM 2001;344:1719-1720.
FULL TEXT
Current topic: New pneumococcal vaccines for children
Choo and Finn
Arch. Dis. Child. 2001;84:289-294.
FULL TEXT
Managing Antibiotic Resistance
Wenzel and Edmond
NEJM 2000;343:1961-1963.
FULL TEXT
Costs of Illness Due to Bordetella pertussis in Families
Lee and Pichichero
Arch Fam Med 2000;9:989-996.
ABSTRACT
| FULL TEXT
Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis
Overturf et al.
Pediatrics 2000;106:367-376.
ABSTRACT
| FULL TEXT
Cost-effectiveness of Pneumococcal Vaccine
Le et al.
JAMA 2000;284:440-441.
FULL TEXT
|
